| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
14,847 |
14,750 |
$1.02M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,658 |
6,469 |
$910K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
19,827 |
18,261 |
$738K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,989 |
1,885 |
$101K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,717 |
1,715 |
$99K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,105 |
4,478 |
$94K |
| 71046 |
Radiologic examination, chest; 2 views |
3,489 |
3,391 |
$92K |
| 99205 |
Prolong outpt/office vis |
1,085 |
1,084 |
$87K |
| 99215 |
Prolong outpt/office vis |
1,409 |
1,363 |
$79K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,557 |
2,433 |
$62K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,377 |
1,369 |
$48K |
| 96127 |
|
7,875 |
7,336 |
$36K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,159 |
5,079 |
$35K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,910 |
1,955 |
$34K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,610 |
1,460 |
$29K |
| 99000 |
|
7,100 |
6,648 |
$25K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
1,355 |
1,014 |
$17K |
| 73630 |
|
694 |
667 |
$16K |
| 93000 |
|
580 |
573 |
$16K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,134 |
1,080 |
$13K |
| 73610 |
|
515 |
498 |
$12K |
| 81003 |
|
6,078 |
5,895 |
$12K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
294 |
241 |
$10K |
| 81025 |
|
2,409 |
2,364 |
$7K |
| 73130 |
|
205 |
197 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,910 |
1,861 |
$4K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
590 |
564 |
$3K |
| 73110 |
|
102 |
102 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
922 |
864 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,883 |
1,854 |
$2K |
| E0114 |
Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips |
51 |
51 |
$2K |
| 99051 |
|
278 |
260 |
$1K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
167 |
163 |
$1K |
| 73562 |
|
53 |
50 |
$1K |
| 87081 |
|
195 |
195 |
$1K |
| 72100 |
|
26 |
26 |
$780.04 |
| 12001 |
|
12 |
12 |
$692.90 |
| 80053 |
Comprehensive metabolic panel |
66 |
66 |
$606.54 |
| 73030 |
|
12 |
12 |
$298.41 |
| 73560 |
|
14 |
14 |
$244.79 |
| 69209 |
|
13 |
13 |
$177.08 |
| 73140 |
|
12 |
12 |
$170.21 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
666 |
629 |
$137.38 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
101 |
99 |
$44.25 |
| 82947 |
|
13 |
13 |
$39.24 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
172 |
167 |
$36.51 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
210 |
205 |
$23.67 |
| J7510 |
Prednisolone oral, per 5 mg |
28 |
28 |
$22.42 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
14 |
14 |
$1.12 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
41 |
41 |
$0.00 |